No Data
No Data
Neurogene Insiders Placed Bullish Bets Worth US$1.46m
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Neurogene Highlights Progress in Rett Syndrome Program
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)
Neurogene Files to Sell 4M Shares of Common Stock for Holders